91 related articles for article (PubMed ID: 32329494)
1. Design and synthesis of glyco-peptides as anti-cancer agents targeting thrombin-protease activated receptor-1 interaction.
Chang YH; Wu JC; Yu HM; Hsu HT; Wu YT; Yu AL; Yu CT; Wong CH
Chem Commun (Camb); 2020 May; 56(43):5827-5830. PubMed ID: 32329494
[TBL] [Abstract][Full Text] [Related]
2. Thrombin-activated receptors: promising targets for cancer therapy?
García-López MT; Gutiérrez-Rodríguez M; Herranz R
Curr Med Chem; 2010; 17(2):109-28. PubMed ID: 19941475
[TBL] [Abstract][Full Text] [Related]
3. Investigation of thrombin activity with PAR 1-based fluorogenic peptides.
Vieira SM; dos Reis FG; Geraldo R; Dutra DL; Juliano L; Julianod MA; Mignaco JA; Zingali RB
Protein Pept Lett; 2013 Oct; 20(10):1129-35. PubMed ID: 23688151
[TBL] [Abstract][Full Text] [Related]
4. Identification of protease exosite-interacting peptides that enhance substrate cleavage kinetics.
Jabaiah AM; Getz JA; Witkowski WA; Hardy JA; Daugherty PS
Biol Chem; 2012 Sep; 393(9):933-41. PubMed ID: 22944693
[TBL] [Abstract][Full Text] [Related]
5. Thrombin Exosite Maturation and Ligand Binding at ABE II Help Stabilize PAR-Binding Competent Conformation at ABE I.
Billur R; Sabo TM; Maurer MC
Biochemistry; 2019 Feb; 58(8):1048-1060. PubMed ID: 30672691
[TBL] [Abstract][Full Text] [Related]
6. Synthesis of Arylpiperazine Derivatives as Protease Activated Receptor 1 Antagonists and Their Evaluation as Antiproliferative Agents.
Zotti AI; Di Gennaro E; Corvino A; Frecentese F; Magli E; Perissutti E; Cirino G; Roviezzo F; Terranova-Barberio M; Iannelli F; Caliendo G; Santagada V; Fiorino F; Budillon A; Severino B
Anticancer Agents Med Chem; 2017; 17(7):973-981. PubMed ID: 27671294
[TBL] [Abstract][Full Text] [Related]
7. Protease-activated receptor-4 uses dual prolines and an anionic retention motif for thrombin recognition and cleavage.
Jacques SL; Kuliopulos A
Biochem J; 2003 Dec; 376(Pt 3):733-40. PubMed ID: 13678420
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of angiogenesis by small-molecule antagonists of protease-activated receptor-1.
Tsopanoglou NE; Maragoudakis ME
Semin Thromb Hemost; 2007 Oct; 33(7):680-7. PubMed ID: 18000795
[TBL] [Abstract][Full Text] [Related]
9. Structural and Functional Characterization of Hirudin P6 Derived Novel Bivalent Thrombin Inhibitors - Studying the Effect of Linker Length and Glycosylation on Their Function.
Shabareesh P; Kaur KJ
Chem Biol Drug Des; 2016 Jul; 88(1):129-41. PubMed ID: 26850929
[TBL] [Abstract][Full Text] [Related]
10. Protease-activated receptor 4 uses anionic residues to interact with alpha-thrombin in the absence or presence of protease-activated receptor 1.
Nieman MT
Biochemistry; 2008 Dec; 47(50):13279-86. PubMed ID: 19053259
[TBL] [Abstract][Full Text] [Related]
11. Protease-activated receptors (PARs)--biology and role in cancer invasion and metastasis.
Wojtukiewicz MZ; Hempel D; Sierko E; Tucker SC; Honn KV
Cancer Metastasis Rev; 2015 Dec; 34(4):775-96. PubMed ID: 26573921
[TBL] [Abstract][Full Text] [Related]
12. Activated coagulation factors in human malignant effusions and their contribution to cancer cell metastasis and therapy.
Gieseler F; Lühr I; Kunze T; Mundhenke C; Maass N; Erhart T; Denker M; Beckmann D; Tiemann M; Schulte C; Dohrmann P; Cavaillé F; Godeau F; Gespach C
Thromb Haemost; 2007 Jun; 97(6):1023-30. PubMed ID: 17549306
[TBL] [Abstract][Full Text] [Related]
13. Thrombin induces tumor growth, metastasis, and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype.
Nierodzik ML; Karpatkin S
Cancer Cell; 2006 Nov; 10(5):355-62. PubMed ID: 17097558
[TBL] [Abstract][Full Text] [Related]
14. Characterization of thrombin-bound dabigatran effects on protease-activated receptor-1 expression and signaling in vitro.
Chen B; Soto AG; Coronel LJ; Goss A; van Ryn J; Trejo J
Mol Pharmacol; 2015 Jul; 88(1):95-105. PubMed ID: 25934730
[TBL] [Abstract][Full Text] [Related]
15. Molecular targeting of breast and colon cancer cells by PAR1 mediated apoptosis through a novel pro-apoptotic peptide.
Ray T; Kar D; Pal A; Mukherjee S; Das C; Pal A
Apoptosis; 2018 Dec; 23(11-12):679-694. PubMed ID: 30196356
[TBL] [Abstract][Full Text] [Related]
16. Thrombin-Induced Podocyte Injury Is Protease-Activated Receptor Dependent.
Sharma R; Waller AP; Agrawal S; Wolfgang KJ; Luu H; Shahzad K; Isermann B; Smoyer WE; Nieman MT; Kerlin BA
J Am Soc Nephrol; 2017 Sep; 28(9):2618-2630. PubMed ID: 28424276
[TBL] [Abstract][Full Text] [Related]
17. Protease-activated receptor 1 knockout reduces experimentally induced liver fibrosis.
Rullier A; Gillibert-Duplantier J; Costet P; Cubel G; Haurie V; Petibois C; Taras D; Dugot-Senant N; Deleris G; Bioulac-Sage P; Rosenbaum J
Am J Physiol Gastrointest Liver Physiol; 2008 Jan; 294(1):G226-35. PubMed ID: 17962354
[TBL] [Abstract][Full Text] [Related]
18. Matrix metalloproteinase-1 and thrombin differentially activate gene expression in endothelial cells via PAR-1 and promote angiogenesis.
Blackburn JS; Brinckerhoff CE
Am J Pathol; 2008 Dec; 173(6):1736-46. PubMed ID: 18988801
[TBL] [Abstract][Full Text] [Related]
19. Tissue factor-factor VIIa complex triggers protease activated receptor 2-dependent growth factor release and migration in ovarian cancer.
Chanakira A; Westmark PR; Ong IM; Sheehan JP
Gynecol Oncol; 2017 Apr; 145(1):167-175. PubMed ID: 28148395
[TBL] [Abstract][Full Text] [Related]
20. Studies on the receptors mediating responses of osteoblasts to thrombin.
Song SJ; Pagel CN; Pike RN; Mackie EJ
Int J Biochem Cell Biol; 2005 Jan; 37(1):206-13. PubMed ID: 15381162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
